# Phase I/II Clinical Study to Evaluate the Safety, Tolerability and Efficacy of LY-M003 Injection in Adult Patients With Wilson's Disease

> **NCT07641140** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **Lingyi Biotech Co., Ltd.** · enrollment: 18 (estimated)

## Conditions studied

- Wilson's Disease

## Interventions

- **GENETIC:** LY-M003 Injection
- **GENETIC:** LY-M003 Injection
- **GENETIC:** LY-M003 Injection

## Key facts

- **NCT ID:** NCT07641140
- **Lead sponsor:** Lingyi Biotech Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-06-15
- **Primary completion:** 2027-12-30
- **Final completion:** 2032-12-30
- **Target enrollment:** 18 (ESTIMATED)
- **Last updated:** 2026-07-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07641140

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07641140, "Phase I/II Clinical Study to Evaluate the Safety, Tolerability and Efficacy of LY-M003 Injection in Adult Patients With Wilson's Disease". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT07641140. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*